ArticleBone reports2026
Early intermittent low-dose sclerostin antibody treatment promotes surface bone formation and reduces bone loss, but also decreases osteocyte apoptosis and mechanotransduction in ovariectomized rats: A pilot study.
Syeda Masooma Naqvi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.